Sage and Biogen Report Results of Zuranolone in P-III WATERFALL Study for Major Depressive Disorder
Shots:
- The P-III WATERFALL study involves assessing the efficacy and safety of zuranolone (50mg- once-nightly for 2wks.) in 543 adults aged 18-64yrs. with MDD with a HAMD-17 total score ≥24 at screening and day 1 prior to dosing
- The study met its 1EPs demonstrating improvement in depressive symptoms @day15 as assessed by the HAMD-17 total score (-14.1 vs -12.3); mean SD baseline HAMD-17 score at entry into the study (26.8 vs 26.9); TEAEs (60.1% vs 44.6%)
- Zuranolone is an investigational oral NAS GABA-A receptor PAM and has received BTD from the US FDA. The therapy is currently being evaluated as a potential rapid-acting- 2wks. treatment for PPD and MDD in the NEST and LANDSCAPE studies
Ref: Business Wire | Image:Biogen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com